# Endemic Mycoses

## Overview

### The Dimorphic Fungi

The endemic mycoses are caused by a group of fungi that exhibit temperature-dependent dimorphism, existing as environmental molds at 25 degrees Celsius and converting to yeast forms in human tissue at 37 degrees Celsius. This dimorphic characteristic is the defining feature of the group. | Feature | Histoplasmosis | Blastomycosis | Coccidioidomycosis | Talaromycosis |
| --- | --- | --- | --- | --- | --- |
| Organism | H. capsulatum | B. dermatitidis | C. immitis / C. posadasii | T. marneffei |  |
| Endemic area | Ohio/Mississippi River valleys, Central America | Great Lakes, Ohio/Mississippi valleys, St. Lawrence | Southwest US (AZ, CA Central Valley), Mexico | Southeast Asia |  |
| Exposure source | Bird/bat droppings, caves, demolition | Waterways, moist soil, decaying organic matter | Desert soil, construction, dust storms | Bamboo rats (reservoir) |  |
| Tissue morphology | 2-4 µm yeast in macrophages (intracellular) | 8-15 µm broad-based budding yeast | 30-60 µm spherules with endospores | Yeast with central septum (fission) |  |
| Key diagnostic test | Urine antigen (90-95% for disseminated) | Culture + histopathology (serology unreliable) | Serology (CF titer correlates with severity) | Culture (red pigment at 25°C) |  |
| Mild disease Tx | Itraconazole 6-12 weeks | Itraconazole 6-12 months | Observation or fluconazole | — |  |
| Severe/disseminated Tx | Amphotericin B → itraconazole ≥12 months | Amphotericin B → itraconazole 12 months | Amphotericin B → fluconazole; meningitis = lifelong FLU | Amphotericin B → itraconazole |  |

The four classic endemic mycoses are caused by Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis and posadasii, and Talaromyces (formerly Penicillium) marneffei, which is endemic to Southeast Asia. Paracoccidioides brasiliensis, endemic to Latin America, is less commonly encountered on US fellowship examinations. A critically important characteristic that distinguishes the endemic mycoses from most other invasive fungal infections is their capacity to cause disease in immunocompetent hosts. Reactivation of latent infection may occur in immunosuppressed patients, including those receiving TNF-alpha inhibitors, transplant recipients, and individuals with HIV.

## Histoplasmosis

### Epidemiology and Ecology

Histoplasma capsulatum var. capsulatum is endemic to the Ohio and Mississippi River valleys, Central America, and the Caribbean. The organism is found in soil enriched with bird or bat droppings, with classic exposure settings including caves, chicken coops, and old buildings undergoing demolition or renovation. Infection occurs through inhalation of microconidia, and seroprevalence in endemic areas reaches 60 to 80 percent, reflecting the widespread nature of subclinical exposure.

### Clinical Syndromes

Acute pulmonary histoplasmosis is asymptomatic or self-limited in approximately 90 percent of cases, manifesting as a mild flu-like illness. In patients with heavy inoculum exposure, such as spelunkers or demolition workers, pneumonia with mediastinal lymphadenopathy may develop. Chronic cavitary histoplasmosis occurs in patients with underlying COPD and resembles tuberculosis, presenting with upper lobe cavitation and progressive disease. Disseminated histoplasmosis occurs in immunocompromised patients, particularly those with HIV and CD4 counts below 150, those receiving TNF-alpha inhibitors, and transplant recipients, presenting with fever, weight loss, hepatosplenomegaly, pancytopenia, mucocutaneous ulcers, and adrenal insufficiency. Mediastinal complications include mediastinal granuloma, which is benign and usually self-limited, and fibrosing mediastinitis, a rare but devastating complication in which fibrotic tissue encases and compresses mediastinal structures. Pericarditis during acute histoplasmosis is a self-limited inflammatory process treated with NSAIDs and not with antifungal therapy.

### Diagnosis

The Histoplasma urine antigen, measured by the MVista enzyme immunoassay, achieves sensitivity of 90 to 95 percent for disseminated disease and 75 percent for acute pulmonary disease, though it cross-reacts with Blastomyces and Coccidioides antigens. Serum antigen testing demonstrates sensitivity of 80 to 90 percent for disseminated disease. Serology using complement fixation and immunodiffusion is most useful for chronic and subacute forms of disease, with H and M bands on immunodiffusion being characteristic and complement fixation titers of 1:32 or above suggestive of active disease, though these tests require four to six weeks to become positive. Culture is the gold standard but is slow, requiring two to four weeks, and can be performed on bone marrow, blood using lysis centrifugation techniques, and tissue specimens. Histopathology reveals 2 to 4 micrometer yeast forms within macrophages on GMS or PAS staining, demonstrating a characteristic "pseudocapsule."

### Treatment

Mild-to-moderate acute pulmonary histoplasmosis with symptoms persisting beyond four weeks is treated with itraconazole 200 milligrams orally three times daily for three days as a loading dose, followed by 200 milligrams orally twice daily for 6 to 12 weeks. Moderate-to-severe and disseminated disease requires induction with liposomal amphotericin B at 3 to 5 milligrams per kilogram per day for one to two weeks, followed by step-down to itraconazole 200 milligrams orally twice daily for a minimum of 12 months. HIV-associated disseminated histoplasmosis is treated with liposomal amphotericin B induction followed by itraconazole maintenance, with secondary prophylaxis using itraconazole 200 milligrams daily continued until the CD4 count exceeds 150 for at least six months on ART. Itraconazole requires therapeutic drug monitoring, with a target random level above 1 microgram per milliliter measured by HPLC rather than bioassay. Absorption of itraconazole requires an acidic gastric pH, and patients on proton pump inhibitors should take the medication with cola or use the solution formulation to ensure adequate bioavailability. Urine Histoplasma antigen levels should be followed during treatment, as a decline correlates with clinical improvement.

<image>A geographic distribution map of the endemic mycoses in the Americas overlaid on a map of the United States and Central/South America. Show: Histoplasma capsulatum distribution (Ohio/Mississippi River valleys, Central America) in blue shading, Blastomyces dermatitidis distribution (Great Lakes, Ohio/Mississippi valleys, St. Lawrence River) in green shading, Coccidioides immitis/posadasii distribution (Southwest US - Arizona, California Central Valley, Northern Mexico) in orange shading. Include overlapping regions where multiple species are endemic. Add icons for key exposure sources: bird/bat droppings for Histoplasma, decaying organic matter near waterways for Blastomyces, desert dust/construction for Coccidioides. Use a clean epidemiologic map style with a legend.</image>

## Blastomycosis

### Epidemiology

Blastomyces dermatitidis is endemic to the Great Lakes states, the Ohio and Mississippi River valleys, and the St. Lawrence River area. The organism is associated with waterways, decaying organic matter, and moist soil. Outbreaks have been associated with outdoor activities near water, including canoeing, fishing, and construction work.

### Clinical Syndromes

Acute pulmonary blastomycosis presents as pneumonia with lobar consolidation that may mimic bacterial community-acquired pneumonia and can progress to ARDS with a mortality rate of 10 to 15 percent. Chronic pulmonary blastomycosis may present with mass lesions mimicking lung cancer or fibronodular disease resembling tuberculosis. Cutaneous blastomycosis is present in 40 to 80 percent of extrapulmonary cases and manifests as verrucous or warty, heaped-up lesions or ulcerative lesions that are characteristically painless and can mimic squamous cell carcinoma. Osteoarticular involvement, seen in 10 to 25 percent of disseminated cases, includes vertebral osteomyelitis and long bone involvement. Genitourinary involvement, manifesting as prostatitis and epididymitis in men, is unique to blastomycosis among the endemic mycoses. CNS involvement with meningitis or brain abscess is rare at approximately 5 percent but is more common in HIV-associated disease. Disseminated blastomycosis can involve all organ systems and is more severe in immunocompromised patients.

### Diagnosis

Culture grows within one to four weeks and reveals broad-based budding yeast on wet preparation or histopathology, with yeast cells measuring 8 to 15 micrometers and demonstrating a single broad-based bud with a thick refractile cell wall. Histopathology is definitive, with the broad-based budding yeast showing a characteristically wide attachment between the parent cell and bud, which is the classic distinguishing feature of this organism. The urine Blastomyces antigen, measured by MVista, achieves a sensitivity of 75 to 90 percent for disseminated disease but cross-reacts with Histoplasma antigen. Serology has poor sensitivity and specificity and is not recommended for diagnosis. PCR is available but not widely standardized.

### Treatment

Mild-to-moderate pulmonary or extrapulmonary blastomycosis is treated with itraconazole 200 milligrams orally three times daily for three days followed by 200 milligrams twice daily for 6 to 12 months. Moderate-to-severe disease, ARDS, and CNS involvement require induction with liposomal amphotericin B at 3 to 5 milligrams per kilogram per day for one to two weeks, followed by itraconazole 200 milligrams twice daily for 12 months. CNS blastomycosis specifically requires liposomal amphotericin B at 5 milligrams per kilogram per day for four to six weeks, followed by an oral azole with better CNS penetration than itraconazole, such as fluconazole at 800 milligrams daily or voriconazole, for a minimum of 12 months. Itraconazole TDM should target a random level above 1 microgram per milliliter.

## Coccidioidomycosis

### Epidemiology

Coccidioidomycosis is caused by Coccidioides immitis in California and C. posadasii in Arizona, New Mexico, Texas, Mexico, and South America. Known as "Valley fever," the infection results from inhalation of arthroconidia released from desert soil during disruption from construction, earthquakes, and dust storms. The disease is highly endemic in Arizona and California's Central Valley, with incidence increasing dramatically. Coccidioides is a BSL-3 pathogen in the laboratory due to its highly infectious arthroconidia.

### Clinical Syndromes

Primary pulmonary coccidioidomycosis is asymptomatic in approximately 60 percent of cases, with symptomatic patients presenting with a flu-like illness including cough, fever, and fatigue. Erythema nodosum or erythema multiforme, known as the "valley fever" rash, is actually a favorable prognostic sign indicating a robust immune response. The infection may present as community-acquired pneumonia. Pulmonary complications include incidental pulmonary nodules, thin-walled coccidioidal cavities, and chronic fibrocavitary disease.

Disseminated disease occurs in 1 to 5 percent of infections, with higher risk in immunocompromised patients, Filipino and African American individuals, and pregnant women in the third trimester. Cutaneous dissemination manifests as papules, pustules, plaques, ulcers, and verrucous lesions. Bone and joint involvement, commonly affecting the vertebrae, knee, and wrist, produces joint effusions. Coccidioidal meningitis presents as a basilar meningitis with hydrocephalus and cranial nerve palsies, and CSF eosinophilia, present in approximately 70 percent of cases, is a classic finding. Complement-fixing antibody in the CSF is diagnostic of coccidioidal meningitis. Miliary dissemination to the peritoneum, liver, and spleen can also occur.

### Diagnosis

Serology is the most important diagnostic tool for coccidioidomycosis. IgM measured by tube precipitin appears early in infection during the first one to three weeks with a sensitivity of 75 percent. IgG measured by complement fixation rises later, and the titer correlates with disease severity, with values of 1:16 or above suggesting disseminated disease. IgG complement fixation titers are also used to monitor treatment response. EIA-based IgM and IgG serve as screening tests and should be confirmed with immunodiffusion and complement fixation. Culture grows in three to seven days but is dangerous, requiring laboratory notification and BSL-3 handling once the mold phase is identified, as arthroconidia are highly infectious. In tissue, the organism forms pathognomonic spherules measuring 30 to 60 micrometers filled with endospores measuring 2 to 5 micrometers. Urine and serum Coccidioides antigen, measured by MVista, achieves a sensitivity of approximately 70 percent in severe or disseminated disease but is less well established than the Histoplasma antigen.

### Treatment

Mild primary pulmonary coccidioidomycosis in immunocompetent patients is managed with observation alone in most cases. Fluconazole 400 milligrams daily should be considered for patients with high-risk features including immunosuppression, high complement fixation titer above 1:16, extensive disease, prolonged symptoms beyond two months, and diabetes. Moderate-to-severe or disseminated non-meningeal disease is treated with fluconazole 400 to 800 milligrams daily or itraconazole 200 milligrams twice daily, with treatment duration of at least 12 to 18 months, and many patients require lifelong suppressive therapy. Coccidioidal meningitis requires fluconazole at 400 to 800 milligrams daily, with some experts using 800 to 1,200 milligrams, and this therapy must be continued lifelong because the relapse rate exceeds 75 percent if therapy is discontinued. Intrathecal amphotericin B is reserved for refractory meningitis. Severe diffuse pneumonia with respiratory failure is treated with liposomal amphotericin B at 3 to 5 milligrams per kilogram per day followed by oral azole step-down therapy. In pregnancy, amphotericin B is the treatment of choice because azole antifungals are teratogenic.

<image>A histopathology and clinical comparison of the three major endemic mycoses. Three columns: "Histoplasmosis," "Blastomycosis," and "Coccidioidomycosis." For each, show: (1) Tissue histopathology image: Histoplasma showing 2-4 micrometer yeast within macrophages (intracellular, narrow-based budding), Blastomyces showing 8-15 micrometer thick-walled yeast with broad-based budding, Coccidioides showing 30-60 micrometer spherules filled with endospores. (2) Below each histopathology, show a characteristic clinical photograph: Histoplasma showing oral mucocutaneous ulcer, Blastomyces showing verrucous skin lesion, Coccidioides showing erythema nodosum (shin nodules). (3) Below each clinical image, list key diagnostic tests and first-line treatment. Use GMS stain appearance for histopathology panels. Medical illustration style with labeled features.</image>

## Talaromyces marneffei

### Epidemiology

Talaromyces marneffei is endemic to Southeast Asia, including Thailand, Vietnam, southern China, and Myanmar. The primary risk group consists of patients with HIV and CD4 counts below 100, though other immunosuppressed individuals are also susceptible. Talaromycosis represents the third most common opportunistic infection in HIV patients in endemic areas, after tuberculosis and cryptococcosis.

### Clinical Features

Disseminated disease presents with fever, weight loss, anemia, lymphadenopathy, and hepatosplenomegaly. Cutaneous involvement, present in approximately 70 percent of cases, manifests as umbilicated papules that resemble molluscum contagiosum. Diagnosis is established by culture, which demonstrates mold growth at 25 degrees Celsius, yeast growth at 37 degrees Celsius, and characteristic red pigment production at 25 degrees Celsius. Histopathology reveals intracellular yeast forms with a central septum, as the organism divides by fission rather than budding. Treatment consists of liposomal amphotericin B for two weeks followed by itraconazole 200 milligrams twice daily for 10 weeks, with secondary prophylaxis using itraconazole continued until the CD4 count exceeds 100 for six months on ART.

## Key Clinical Pearls

- Endemic mycoses cause disease in IMMUNOCOMPETENT hosts -- always consider travel history and geographic exposure
- Histoplasma urine antigen has excellent sensitivity (>90%) for disseminated histoplasmosis -- use it as a first-line test in the right clinical setting
- Blastomycosis has the most unreliable serology of the endemic mycoses -- diagnosis relies on culture and histopathology (broad-based budding yeast)
- Coccidioidal meningitis requires LIFELONG fluconazole -- relapse rate exceeds 75% if therapy is discontinued
- CSF eosinophilia is highly characteristic of coccidioidal meningitis and should prompt serologic testing
- Erythema nodosum in a patient from Arizona or California's Central Valley should trigger coccidioidomycosis testing
- All dimorphic fungi cross-react on antigen testing (Histoplasma, Blastomyces, Coccidioides, Talaromyces) -- clinical context is essential for interpretation
- Itraconazole requires acidic gastric pH for absorption -- co-administration with PPIs reduces levels; use solution formulation or capsules with cola

## References
1. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the IDSA. *Clin Infect Dis*. 2007;45(7):807-825.
2. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the IDSA. *Clin Infect Dis*. 2008;46(12):1801-1812.
3. Galgiani JN, Ampel NM, Blair JE, et al. 2016 IDSA clinical practice guideline for the treatment of coccidioidomycosis. *Clin Infect Dis*. 2016;63(6):e112-e146.
4. Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in Southeast Asia. *Lancet*. 1994;344(8915):110-113.
5. Benedict K, Thompson GR III, Deresinski S, Chiller T. Mycotic infections acquired outside areas of known endemicity, United States. *Emerg Infect Dis*. 2015;21(11):1935-1941.